Business Context and Reporting Period
This Form 8-K was filed by Ventrus Biosciences, Inc. on April 4, 2014. The report addresses a specific regulatory event regarding the company's product pipeline rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a regulatory milestone and does not contain financial statements.
Material Changes
The material event reported is the scheduling of a Type B pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA). The meeting is set for June 19, 2014, to seek guidance on the planned NDA for DOLIZEM (diltiazem hydrochloride cream) for the treatment of anal fissures.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA meeting. The filing does not provide specific financial guidance, outlook, or a detailed discussion of risks and contingencies beyond the inherent uncertainty of the regulatory review process for DOLIZEM.
Investor Verification Checklist
- Verify the outcome of the FDA Type B pre-NDA meeting scheduled for June 19, 2014.
- Confirm the status of the DOLIZEM (diltiazem hydrochloride cream) development program.
- Review subsequent filings for any financial impact resulting from the regulatory timeline.